Consumer medicine information

Spikevax COVID-19 Vaccine

Elasomeran

BRAND INFORMATION

Brand name

Spikevax

Active ingredient

Elasomeran

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Spikevax COVID-19 Vaccine.

1. Why am I being given SPIKEVAX?

SPIKEVAX contains the active ingredient Elasomeran. SPIKEVAX is a vaccine which stimulates the body’s natural defences (immune system). The vaccine works by causing the body to produce protection (antibodies) against the virus that causes COVID-19 disease. SPIKEVAX uses a substance called messenger ribonucleic acid (mRNA) to carry instructions to cells in the body that are used to make the spike protein that is also on the virus. The cells then make antibodies against the spike protein to help fight off the virus. This will help to protect you against COVID-19 disease.

SPIKEVAX is used to prevent COVID-19 disease caused by SARS-CoV-2. It is given to individuals aged 18 years and older.

2. What should I know before I am given SPIKEVAX?

Warnings

You should not be given SPIKEVAX if:

  • you are allergic to Elasomeran or any of the ingredients listed at the end of this leaflet.
  • Always check the ingredients to make sure you can be given this vaccine.

Check with your doctor, pharmacist, or nurse before vaccination if you:

  • Have previously had a severe, life-threatening allergic reaction after any other vaccine injection or after you were given SPIKEVAX in the past.
  • Have a very weak or compromised immune system.
  • Have ever fainted following any needle injection.
  • Have a bleeding disorder.
  • Have a high fever or severe infection; however, you can have your vaccination if you have a mild fever or upper airway infection like a cold.
  • Have any serious illness.
  • Have anxiety related to injections. Anxiety and stress related reactions can occur, however, they will be temporary.
  • Take any medicines for any other condition.

Very rare cases of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have been reported after vaccination with SPIKEVAX. The cases have primarily occurred within two weeks following vaccination, more often after the second vaccination, and more often occurred in younger men. Following vaccination, you should be alert to signs of myocarditis and pericarditis, such as breathlessness, palpitations and chest pain, and seek immediate medical attention should these occur.

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Pregnancy and breastfeeding

Check with your doctor, pharmacist, or nurse if you are pregnant or intend to become pregnant.

Talk to your doctor, pharmacist, or nurse if you are breastfeeding or intend to breastfeed.

Use in Children

SPIKEVAX is not recommended for children and adolescents aged under 18 years.

3. What if I am taking other medicines?

Tell your doctor, pharmacist, or nurse if you are taking any other medicines, including any medicines, vitamins, or supplements that you buy without a prescription from your pharmacy, supermarket, or health food shop.

Tell your doctor or pharmacist if you have recently received any other vaccine.

Check with your doctor, pharmacist, or nurse if you are not sure about what medicines, vitamins or supplements you are taking and if these affect SPIKEVAX.

Published by MIMS September 2021

BRAND INFORMATION

Brand name

Spikevax

Active ingredient

Elasomeran

Schedule

S4

 

1 Name of Medicine

Elasomeran.

2 Qualitative and Quantitative Composition

This is a multidose vial which contains 10 doses of 0.5 mL.
One dose (0.5 mL) contains 100 micrograms of messenger RNA (mRNA) (embedded in SM-102 lipid nanoparticles). Single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Suspension for injection.
White to off white suspension.

4 Clinical Particulars

4.1 Therapeutic Indications

Spikevax (elasomeran) COVID-19 Vaccine has provisional approval for the indication below:
Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 18 years of age and older.
The use of this vaccine should be in accordance with official recommendations.
The decision has been made on the basis of short-term efficacy and safety data. Continued approval depends on the evidence of longer term efficacy and safety from ongoing clinical trials and post-market assessment.

4.2 Dose and Method of Administration

Spikevax is administered as a course of 2 doses (0.5 mL each). It is recommended to administer the second dose 28 days after the first dose (see Section 4.4 Special Warnings and Precautions for Use; Section 5.1 Pharmacodynamic Properties).
There are no data available on the interchangeability of Spikevax with other COVID-19 vaccines to complete the vaccination course. Individuals who have received the first dose of Spikevax should receive the second dose of Spikevax to complete the vaccination course.
The vaccine should be prepared and administered by a trained healthcare professional using aseptic techniques to ensure sterility of the suspension.
The vaccine comes ready to use once thawed.
Do not shake or dilute.
Swirl the vial gently after thawing and before each withdrawal.
Spikevax vials are multidose. Ten (10) doses (of 0.5 mL each) can be withdrawn from each vial. Pierce the stopper preferably at a different site each time.
An additional overfill is included in each vial to ensure that 10 doses of 0.5 mL can be delivered.
Thawed vials and filled syringes can be handled in room light conditions.
For practical reasons, if the contents of the vial are to be used within a short period of time, drawing up the content in multiple syringes at once may be considered.

Frozen storage.

Store frozen between -25°C to -15°C. Do not store on dry ice or below -50°C.
Store in the original carton to protect from light.

Thaw each vial before use.

2 hours and 30 minutes in refrigerator: 2° to 8°C (within the 30 days shelf life at 2°C to 8°C). Let vial sit at room temperature for 15 minutes before administering.
1 hour at room temperature: 15° to 25°C.

Instructions once thawed.

Unpunctured vial.

Maximum times:
30 days: Refrigerator 2° to 8°C.
24 hours: Cool storage up to room temperature 8° to 25°C.

After first dose has been withdrawn.

Maximum time:
19 hours: refrigerator or room temperature.
Vial should be held between 2° to 25°C. Record the date and time of discard on the vial label.
Discard punctured vial after 19 hours.
Withdraw each 0.5 mL dose of vaccine from the vial using a new sterile needle and syringe for each injection to prevent transmission of infectious agents from one person to another. The dose in the syringe should be used immediately.
Once the vial has been punctured to withdraw the initial dose, the vaccine should be used immediately and be discarded after 19 hours.
Any unused vaccine or waste material should be disposed of in accordance with local requirements.
Never refreeze thawed vaccine.

Administration.

Swirl vial gently after thawing and before each withdrawal.
The vaccine comes ready to use once thawed. Do not shake or dilute.
Prior to injection, inspect each dose to:
Confirm liquid is white to off-white in colour in both vial and syringe.
Verify syringe volume of 0.5 mL.
The Spikevax may contain white or transluscent product-related particulates.
If dosage is incorrecct, or discolouration and other particulate matter is present, do not administer the vaccine.

Paediatric population.

The safety and efficacy of Spikevax in children and adolescents less than 18 years of age have not yet been established. No data are available.

Elderly population.

No dosage adjustment is required in elderly individuals ≥ 65 years of age.

Method of administration.

The vaccine should be administered intramuscularly.
The preferred site is the deltoid muscle of the upper arm.
Do not administer this vaccine intravascularly, subcutaneously or intradermally.
The vaccine should not be mixed in the same syringe with any other vaccines or medicinal products. For precautions to be taken before administering the vaccine, see Section 4.4 Special Warnings and Precautions for Use.
For instructions regarding thawing, handling, and disposal of the vaccine, see Section 6.6 Special Precautions for Disposal.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed, see Section 6.1 List of Excipients.

4.4 Special Warnings and Precautions for Use

Traceability.

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Hypersensitivity and anaphylaxis.

Anaphylaxis has been reported in individuals who have received Spikevax. Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic reaction following administration of the vaccine.
Close observation is recommended following vaccination as follows:

30 minutes.

People with a history of an immediate allergic reaction of any severity to another vaccine or injectable therapy.
People with a history of anaphylaxis due to any cause.

15 minutes.

All other persons.
The second dose of the vaccine should not be given to those who have experienced anaphylaxis to the first dose of Spikevax.

Myocarditis and pericarditis.

There have been very rare reports of myocarditis and pericarditis occurring after vaccination with Spikevax.
These cases have primarily occurred within 14 days following the vaccination, more often after the second dose, and more often in younger men. Available data suggest that the course of myocarditis and pericarditis following vaccination is not different from myocarditis or pericarditis in general.
Healthcare professionals should be alert to the signs and symptoms of myocarditis and pericarditis.
Vaccine recipients should be instructed to seek immediate medical attention if they develop symptoms indicative of myocarditis or pericarditis such as (acute and persisting) chest pain, shortness of breath, or palpitations following vaccination. Healthcare professionals should consult guidance and/or specialists to diagnose and treat this condition.
For further details, please refer to the relevant clinical guidelines developed by the Australian Technical Advisory Group on Immunisation.

Anxiety-related reactions.

Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress‐related reactions may occur in association with vaccination as a psychogenic response to the needle injection. It is important that precautions are in place to avoid injury from fainting.

Concurrent illness.

Vaccination should be postponed in individuals suffering from acute severe febrile illness or acute infection. The presence of a minor infection and/or low-grade fever should not delay vaccination.

Thrombocytopenia and coagulation disorders.

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.

Immunocompromised individuals.

The efficacy, safety and immunogenicity of the vaccine has not been assessed in immunocompromised individuals, including those receiving immunosuppressant therapy. The efficacy of Spikevax may be lower in immunosuppressed individuals.

Duration of protection.

The duration of protection afforded by the vaccine is unknown as it is still being determined by ongoing clinical trials.

Limitations of vaccine effectiveness.

Individuals may not be fully protected until 14 days after their second dose. As with all vaccines, vaccination with Spikevax may not protect all vaccine recipients.

Excipients with known effect.

Sodium.

This vaccine contains less than 1 mmol sodium (23 mg) per 0.5 mL dose, that is to say, essentially 'sodium-free'.

Use in the elderly.

Spikevax was assessed in individuals 18 years of age and older, including 3,768 subjects 65 years of age and older. The efficacy of Spikevax was consistent between elderly (≥ 65 years) and younger adult subjects (18-64 years).

Paediatric use.

The safety and efficacy of Spikevax in children and adolescents less than 18 years of age have not yet been established. No data are available.

Effects on laboratory tests.

No data available.

4.5 Interactions with Other Medicines and Other Forms of Interactions

No interaction studies have been performed. Concomitant administration of Spikevax with other vaccines has not been studied.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity in females.
In a combined fertility and developmental toxicity study, 100 micrograms of mRNA (elasomeran) and other ingredients included in a single human dose of Spikevax was administered to female rats by the intramuscular route on four occasions: 28 and 14 days prior to mating, and on gestation days 1 and 13. SARS-CoV-2 antibody responses were present in dams from prior to mating to the end of the study on lactation day 21 as well as in fetuses and offspring. There were no vaccine-related adverse effects on female fertility, pregnancy, embryofetal or offspring development or postnatal development. No data are available on Spikevax vaccine placental transfer or excretion in milk. The effect on male fertility has not been determined.
(Category B1)
There is limited experience with use of Spikevax in pregnant women.
A combined fertility and development toxicity study in rats did not show vaccine-related harmful effects on embryofetal development (see Effects on fertility).
Administration of Spikevax in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and fetus.
It is unknown whether Spikevax is excreted in human milk. A combined fertility and developmental toxicity study in rats did not show harmful effects on offspring development before weaning (see Effects on fertility).

4.7 Effects on Ability to Drive and Use Machines

Spikevax has no or negligible influence on the ability to drive and use machines. However, some of the effects mentioned, see Section 4.8 Adverse Effects (Undesirable Effects) may temporarily affect the ability to drive or use machines.

4.8 Adverse Effects (Undesirable Effects)

The safety of Spikevax was evaluated in an ongoing Phase 3 randomised, placebo-controlled, observer-blind clinical study conducted in the United States involving 30,351 participants, 18 years of age and older, who received at least one dose of Spikevax (n = 15,185) or placebo (n = 15,166) (NCT04470427). At the time of vaccination, the mean age of the population was 52 years (range 18-95); 22,831 (75.2%) of participants were 18 to 64 years of age and 7,520 (24.8%) of participants were 65 years of age and older.
The most frequently reported adverse reactions were pain at the injection site (92%), fatigue (70%), headache (64.7%), myalgia (61.5%), arthralgia (46.4%), chills (45.4%), nausea/vomiting (23%), axillary swelling/tenderness (19.8%), fever (15.5%), injection site swelling (14.7%) and redness (10%). Adverse reactions were usually mild or moderate in intensity and resolved within a few days after vaccination. A slightly lower frequency of reactogenicity events was associated with greater age.
Delayed injection site reactions that began > 7 days after vaccination were reported in 1.2% of vaccine recipients and 0.4% of placebo recipients. Delayed injection site reactions included pain, erythema, and swelling, and are likely related to vaccination.
Overall, there was a higher incidence of some adverse reactions in younger age groups: the incidence of axillary swelling/tenderness, fatigue, headache, myalgia, arthralgia, chills, nausea/vomiting, and fever was higher in adults aged 18 to < 65 years than in those aged 65 years and above. Local and systemic adverse reactions were more frequently reported after Dose 2 than after Dose 1.
The safety profile presented in Table 1 is based on data generated in a placebo-controlled clinical study on 30,351 adults ≥ 18 years of age.
Adverse reactions reported are listed according to the following frequency convention:
Very common (≥ 1/10); Common (≥ 1/100 to < 1/10); Uncommon (≥ 1/1,000 to < 1/100); Rare (≥ 1/10,000 to < 1/1,000); Very rare (< 1/10,000); Not known (cannot be estimated from the available data).
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
The reactogenicity and safety profile in 343 subjects receiving Spikevax, who were seropositive for SARS-CoV-2 at baseline, was comparable to that in subjects seronegative for SARS-CoV-2 at baseline.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

No case of overdose has been reported.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Pharmacotherapeutic group: Vaccine, other viral vaccines, ATC code: J07BX03.

Mechanism of action.

Spikevax contains mRNA encapsulated in lipid nanoparticles. The mRNA encodes for the full-length SARS-CoV-2 spike protein modified with 2 proline substitutions within the heptad repeat 1 domain (S-2P) to stabilise the spike protein into a prefusion conformation. After intramuscular injection, cells at the injection site and the draining lymph nodes take up the lipid nanoparticle, effectively delivering the mRNA sequence into cells for translation into viral spike protein. The delivered mRNA does not enter the cellular nucleus or interact with the genome, is nonreplicating, and is expressed transiently mainly by dendritic cells and subcapsular sinus macrophages. The expressed, membrane-bound spike protein of SARS-CoV-2 is then recognised by immune cells as a foreign antigen. This elicits both T-cell and B-cell responses to generate neutralising antibodies, which may contribute to protection against COVID-19.

Clinical trials.

Study 1 was a randomised, placebo-controlled, observer-blind Phase 3 clinical study (NCT04470427) that excluded individuals who were immunocompromised or who had received immunosuppressants within 6 months, as well as participants who were pregnant, or with a known history of SARS-CoV-2 infection. Participants with stable HIV disease were not excluded. Influenza vaccines could be administered 14 days before or 14 days after any dose of Spikevax. Participants were also required to observe a minimum interval of 3 months after receipt of blood/plasma products or immunoglobulins prior to the study in order to receive either placebo or Spikevax.
A total of 30,351 subjects were followed for a median of 92 days (range: 1-122) for the development of COVID-19 disease.
COVID-19 was defined as symptomatic COVID-19 requiring positive RT-PCR result and at least 2 systemic symptoms or 1 respiratory symptom. Cases starting 14 days after the second dose.
The primary efficacy analysis population (referred to as the Per Protocol Set or PPS), included 28,207 subjects who received either Spikevax (n = 14,134) or placebo (n = 14,073) and had a negative baseline SARS-CoV-2 status. The PPS study population included 47.4% female, 52.6% male, 79.5% White, 9.7% African American, 4.6% Asian, and 6.2% other. 19.7% of participants identified as Hispanic or Latino. The median age of subjects was 53 years (range 18-94). A dosing window of -7 to +14 days for administration of the second dose (scheduled at day 29) was allowed for inclusion in the PPS. 98% of vaccine recipients received the second dose 25 days to 35 days after dose 1 (corresponding to -3 to +7 days around the interval of 28 days). COVID-19 cases were confirmed by Reverse Transcriptase Polymerase Chain Reaction (RT PCR) and by a Clinical Adjudication Committee. Vaccine efficacy overall and by key age groups are presented in Table 2.
Among all subjects in the PPS, no cases of severe COVID-19 were reported in the vaccine group compared with 30 of 185 (16%) cases reported in the placebo group. Of the 30 participants with severe disease, 9 were hospitalised, 2 of which were admitted to an intensive care unit. The majority of the remaining severe cases fulfilled only the oxygen saturation (SpO2) criterion for severe disease (≤ 93% on room air).
The vaccine efficacy of Spikevax to prevent COVID-19, regardless of prior SARS-CoV-2 infection (determined by baseline serology and nasopharyngeal swab sample testing) from 14 days after Dose 2 was 93.6% (95% confidence interval 88.5, 96.4%).
Additionally, subgroup analyses of the primary efficacy endpoint showed similar efficacy point estimates across genders, ethnic groups, and participants with medical comorbidities associated with high risk of severe COVID-19.

5.2 Pharmacokinetic Properties

Not applicable.

5.3 Preclinical Safety Data

Genotoxicity.

The novel lipid components SM-102 and PEG-2000-DMG of the vaccine were negative in the bacterial reverse mutation Ames test and in vitro micronucleus test in human peripheral blood lymphocytes. A luciferase mRNA in SM102-containing lipid nanoparticles was negative in a rat bone marrow micronucleus assay (IV dose of SM-102 28.5 mg/kg, PEG-2000-DMG 2.8 mg/kg), whilst a surrogate Zika mRNA-based vaccine formulated in SM-102-containing lipid nanoparticles induced micronuclei in male rats, but not in females (IV dose of SM-102 60 mg/kg, PEG-2000-DMG 6 mg/kg). The weight of evidence suggests the genotoxicity potential of the novel lipid components SM-102 and PEG-2000-DMG is very low. The other components of Spikevax (other lipids and mRNA) are not expected to be genotoxic.

Carcinogenicity.

Carcinogenicity studies were not performed. The components of the vaccine (lipids and mRNA) are not expected to have carcinogenic potential.

6 Pharmaceutical Particulars

6.1 List of Excipients

Heptadecan-9-yl 8-[2-hydroxyethyl-(6-oxo-6-undecoxyhexyl)amino]octanoate, cholesterol, distearoylphosphatidylcholine, 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000, trometamol, trometamol hydrochloride, acetic acid, sodium acetate trihydrate, sucrose, water for injections.

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products or diluted.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

Unopened vial.

The unopened vaccine may be stored refrigerated at 2°C to 8°C, protected from light, for maximum 30 days. Once thawed the vaccine should not be re-frozen.
The unopened vaccine may be stored at 8°C to 25°C up to 24 hours after removal from refrigerated conditions.

Punctured vial.

Chemical and physical in-use stability has been demonstrated for 19 hours at 2°C to 25°C after initial puncture (within the allowed use period of 30 days at 2°C to 8°C and 24 hours at 8°C to 25°C). Contains no antimicrobial preservative. From a microbiological point of view, the product should be used immediately.

6.4 Special Precautions for Storage

Store frozen between -25°C to -15°C.
Store in the original carton to protect from light.
Do not store on dry ice or below -50°C.
For storage conditions after thawing and first opening see Section 6.3.

Transportation of thawed vials in liquid state at 2°C to 8°C.

If transport at -50°C to -15°C is not feasible, available data support transportation of one or more thawed vials in liquid state for up to 12 hours at 2°C to 8°C (within the 30 days shelf life at 2°C to 8°C). Once thawed and transported in liquid state at 2°C to 8°C, vials should not be refrozen and should be stored at 2°C to 8°C until use.

6.5 Nature and Contents of Container

5 mL suspension in a vial (type 1 or type 1 equivalent glass) with a stopper (chlorobutyl rubber) and a flip-off plastic cap with seal (aluminium seal).
Each vial contains 10 doses of 0.5 mL.

Pack size.

10 multidose vials.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

6.7 Physicochemical Properties

CAS number.

2457298-05-2.

7 Medicine Schedule (Poisons Standard)

Prescription only medicine (Schedule 4).

Summary Table of Changes